Salarius Pharmaceuticals to be Acquired by Evrensel Group

TL;DR

Salarius Pharmaceuticals is being bought by Evrensel Group, deal expected to close Q4 2024.

AI Summary

Salarius Pharmaceuticals, Inc. announced on July 19, 2024, that it has entered into a definitive agreement to be acquired by Evrensel Group, Inc. The transaction is expected to close in the fourth quarter of 2024, subject to customary closing conditions. This acquisition marks a significant development for Salarius Pharmaceuticals.

Why It Matters

This acquisition could lead to significant changes for Salarius Pharmaceuticals' operations, its stock, and its future development pipeline.

Risk Assessment

Risk Level: medium — The acquisition is subject to closing conditions, and the terms of the deal are not fully detailed, introducing some uncertainty.

Key Players & Entities

• Salarius Pharmaceuticals, Inc. (company) — Company filing the report and being acquired
• Evrensel Group, Inc. (company) — Acquiring company
• July 19, 2024 (date) — Date of the definitive agreement and report
• fourth quarter of 2024 (date) — Expected closing period for the acquisition

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 SLRX The Nasdaq Capital Market Indi

Filing Documents

• flks-20240719.htm (8-K) — 29KB
• 0001615219-24-000058.txt ( ) — 153KB
• flks-20240719.xsd (EX-101.SCH) — 2KB
• flks-20240719_lab.xml (EX-101.LAB) — 22KB
• flks-20240719_pre.xml (EX-101.PRE) — 13KB
• flks-20240719_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. As previously announced, in November 2023, Salarius Pharmaceuticals, Inc. (the "Company") completed a Type B End-of-Phase 2 ("EOP2") meeting with the U.S. Food and Drug Administration (the "FDA) to receive guidance regarding the Company's development program for seclidemstat to treat Ewing sarcoma. The Company subsequently amended its Phase 1/2 clinical trial protocol in January 2024 to reflect guidance from the FDA at the EOP2 meeting. The Company has now determined to close the ongoing Phase 1/2 clinical trial evaluating seclidemstat for Ewing sarcoma, including closing the remaining clinical trial sites. The Company is terminating the ongoing clinical trial in an effort to conserve cash while the Company's Board of Directors continues its exploration of potential strategic alternatives focused on maximizing shareholder value and potential options to continue the clinical development for Ewing sarcoma in the future. The Company intends to continue supporting The University of Texas MD Anderson Cancer Center ("MDACC") in MDACC's sponsored clinical trial evaluating seclidemstat (SP-2577) in combination with azacitidine in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia, which remains on partial clinical hold following a serious and unexpected grade 4 adverse event. Forward Looking Statement Disclaimer This report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this report are forward-looking statements. These forward-looking statements may be identified by terms such as "will," "believe," "developing," "expect," "may," "progress," "potential," "could," "look forward," "encouraging," "might," "should," "intend" and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following: the

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SALARIUS PHARMACEUTICALS, INC. Date: July 19, 2024 By: /s/ Mark J. Rosenblum Mark J. Rosenblum Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR